Harris, J. M., Sheehan, K., Rogers, C. A., Murphy, T., Caputo, M., & Mumford, A. D. (2021). Prediction of Bleeding in Pediatric Cardiac Surgery Using Clinical Characteristics and Prospective Coagulation Test Results. *Seminars in Thoracic and Cardiovascular Surgery*.
<https://doi.org/10.1053/j.semtcvs.2021.01.006>

Peer reviewed version

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1053/j.semtcvs.2021.01.006](https://doi.org/10.1053/j.semtcvs.2021.01.006)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at <https://doi.org/10.1053/j.semtcvs.2021.01.006>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

The Journal of Thoracic and Cardiovascular Surgery

Prediction of bleeding in paediatric cardiac surgery using clinical characteristics and prospective coagulation test results

--Manuscript Draft--

Manuscript Number:	JTCVS-20-1692R2
Full Title:	Prediction of bleeding in paediatric cardiac surgery using clinical characteristics and prospective coagulation test results
Article Type:	Original Manuscript
Section/Category:	CONG: Congenital
Corresponding Author:	andrew mumford, MB ChB PhD University of Bristol School of Clinical Science UNITED KINGDOM
Corresponding Author's Institution:	University of Bristol School of Clinical Science
Corresponding Author's Secondary Institution:	
First Author:	Jessica Harris, BSc
Order of Authors:	Jessica Harris, BSc Karen Sheehan, Msc Chris Rogers, BSc, PhD Tim Murphy, MBBS, FRCA Massimo Caputo, MD, MCh Andrew Mumford, MB ChB PhD
Keywords:	Coagulation testing; paediatric cardiac surgery; bleeding; predictive models; coagulopathy
Additional Information:	
Question	Response
Please submit your article's Central Message here. The text box will limit you to 200 characters, spaces included **NOTE: This MUST ALSO be included in the manuscript file, after the title page.	Prospective coagulation testing offers little additional benefit to prediction of bleeding in children undergoing cardiac surgery when compared to prediction using clinical characteristics alone.
Please submit your article's Perspective Statement here. The text box will limit you to 405 characters, spaces included **NOTE: This MUST ALSO be included in the manuscript file, after the title page.	Excessive bleeding from coagulopathy causes adverse outcomes in children having cardiac surgery. Rapid coagulation testing for diagnosis of coagulopathy improves outcomes but has uncertain utility for prediction of bleeding. We show that prospective coagulation testing does predict bleeding but has little additional value compared to prediction using the clinical characteristics of children alone.
Please submit the abbreviated legend for your Central Picture . The text box will limit you to 90 characters, spaces included **NOTE: This MUST ALSO be included in the manuscript file, after the title page.	Bleeding prediction models improves little after including coagulation test results
Is this manuscript a clinical trial that requires registration at www.clinicaltrials.gov per ICMJE rules? Please see Instructions above for rules. If	no

yes , you must fill in the clinical trial number below to be considered for publication. If no , please put "no" in the response field.	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?	No
Please indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. You should report relationships that were present during the 36 months prior to publication.	No
Do you have any patents, whether planned, pending or issued, broadly relevant to the work?	No
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	No

Prediction of bleeding in paediatric cardiac surgery using clinical characteristics and prospective coagulation test results

Jessica M Harris BSc, MSc, PhD¹, Karen Sheehan MSc², Chris A Rogers BSc, PhD¹, Tim Murphy MBBS FRCA², Massimo Caputo MD MCh^{2,3,4}, Andrew D Mumford MB ChB PhD⁵

1. Bristol Trials Centre, Faculty of Health Sciences, University of Bristol, Bristol, UK.
2. Department of Paediatric Cardiac Surgery, Bristol Royal Hospital for Children, University Hospitals Bristol, Bristol, UK.
3. Bristol Heart Institute, University Hospitals Bristol, Bristol, UK.
4. Department of Paediatric Cardiac Surgery, School of Translational Sciences, University of Bristol, Bristol, UK.
5. Department of Haematology, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Conflicts of Interest: The authors declare no relevant conflicts of interest

Funding statement: The study was supported by the UK National Institute for Health Research through the Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol, and the British Heart Foundation.

Corresponding author: Professor Andrew Mumford, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. Email a.mumford@bristol.ac.uk

Clinical trial registration: ISRCTN55439761

NHS Research Ethics Committee: approval 13/LO/0504 (2013)

Key Words: Coagulation testing; Paediatric Cardiac Surgery; Bleeding; Predictive models; Coagulopathy

Manuscript length: Total 3498 words; Abstract 250 words; Figures 3; Tables 4; Supplementary file 1; References 34

JTCVS-20-1692R1

Prediction of bleeding in paediatric cardiac surgery using clinical characteristics and coagulation test results

1. Response to Seminars editor's comments

There is interest in considering your paper for publication in Seminars given its relevance to the field. However, reviewer comments have pointed out some persistent concerns. In particular, the authors should address the concerns raised by reviewer #2 with respect to the data as presented. The manuscript should also more clearly recognize the limited generalizability, especially given the study design and the very small number of neonates/circulatory arrest procedures. A final decision to publish will be made if these major concerns are adequately addressed.

Response: Thank you for giving us a further opportunity to respond to the reviewer's comments. We are encouraged by the overall positive responses from reviewer 1 and 3 and the statistical editor. Reviewer 4 has highlighted some cautions about interpretation that we have highlighted clearly in the strengths and weaknesses section.

We have now carefully addressed the additional comments from reviewer 2. For most comments, we have made positive changes to the manuscript and in a minority clarified with the reviewer.

The major criticism for reviewer 2 concerned exclusion of neonates (<2.5 Kg) because of a necessary research ethics constraint caused by the relatively large blood volume required for comprehensive coagulation testing. Despite this constraint, we chose not to proceed with a smaller blood sample volume because this would have compromised the scope of coagulation testing for all children in the study. This potentially could have resulted in an underestimate of the utility of prospective coagulation testing.

For complete transparency, we have acknowledged in our discussion that our findings cannot be generalised to the neonatal group (new sentence at lines 381-383 *This constraint precluded inclusion of neonates in which bleeding is prevalent and prevents generalisation of our findings to this age group*'). We don't believe that this devalues the importance of our findings in any of the other age groups which were well represented in our study.

We have made some further small changes to the text without alteration of meaning in order to maintain the word limit of 3,500.

2. Response to reviewers

Reviewer #1: The only suggestion I would make for further clarifying or improving the paper is to further emphasize the difference between the use of coagulation testing to predict vs to treat excessive bleeding. I believe this could be effectively done by stating the former as "prospective laboratory testing" or something similar. This would ensure that the reader is aware of the difference between laboratory testing before any clinical evidence of bleeding is noted.

Response: Thank you for this helpful suggestion. We have amended the manuscript throughout where appropriate.

Changes: The term 'prospective' or 'prospective coagulation tests' has been inserted at the following positions:

Title- page 1

Central picture legend- page 3

Central Message- page 3

Perspective statement- page 3

Abstract-page 4

Introduction- pages 5 and 6

Results- page 12

Discussion- pages 14,15, 16, 17,18

Figure 2 legend- page 24 and 25

Figure 4 (graphical abstract) legend- page 26

Reviewer #2:

1. Clinical management of patients: The authors have revised their primary endpoint from excessive bleeding to clinical concern for bleeding (CCB), parallel to that from a previous adult study by the same group. Their response is still unsatisfactory. The following issues beg for either clarification in the methods, or at the very least some mention of them in the discussion as weaknesses in the study design.

a. Clinical decision making remains subjective, and no clear algorithm or protocol for guiding the decision making has been outlined. This reviewer joins Reviewer 4, in asking for further clarification regarding institutional practices and protocols.

Response: In our revised manuscript, we significantly increased the description of the institutional practices and protocols. Within the manuscript length constraint, we believe that this gives the reader sufficient information relevant to our blood management practice. We have now introduced a new reference from our centre that give more detail about other aspects of anaesthetic and surgical management in place at the time of the study.

Changes: New reference 25 inserted in *Methods* page 7

b. The authors clarify that any transfusion treatment not specifically documented as a response to bleeding is not classified as the primary outcome. This opens the possibility for undermeasurement of the primary outcome. Some estimation of how often this occurred, or inclusion of this as a limitation is requested.

Response: The reviewer correctly identifies that accurate capture of the primary outcome required our clinical teams to identify whether a pro-haemostatic treatment was '*in response to bleeding*' or was a '*pre-planned preventative treatment*'. For every treatment administered during the study interval this was actively recorded on the case report form. All '*treatments in response to bleeding*' identified on the case report form (crf) were checked by the research team to ensure correct designation as part of the primary outcome. This procedure is documented in *Methods* page 8, paragraph 1.

As expected, the vast majority of pro-haemostatic interventions (eg protamine at the end of CPB) were *pre-planned preventative treatments* and therefore were not part of the primary outcome. Haemostatic treatments give at times other than the well demarcated periods during the study interval when *pre-planned preventative treatments* are usually given would have been obvious during the crf review process and correct designation ensured. Therefore, the likelihood of incorrect designation leading to underestimation of the primary outcome is likely zero or very low. We have amended the 'strengths and limitations' section to recognise this as a small possibility.

Changes: Sentence '*Conversely a very small number of children may have received treatments in response to bleeding that were not documented as such.*' Has now been inserted into *Discussion* page 17, paragraph 1.

2. Clarity of the models: Although the authors explain to the statistical editor that the fractional polynomial method was chosen to account for nonlinearity of terms, the very process of the fractional polynomial regression method remains totally opaque. Statistical processes should be explained to the readership in sufficient detail such that if the authors were to send the reader a copy of their data file, the reader should be able to follow their methods and reproduce their findings. If the details are lengthy or technically tedious, then a supplemental online file or reference to previously published methods (again, with sufficient detail) may be provided.

Response: In the previous revision we included a reference for readers who may be unfamiliar with this approach (reference #27). We have also edited the text slightly and named the Stata command. We believe the information provided details the steps taken in sufficient detail that would allow for reproduction by a

statistician (as these methods are not likely to be undertaken by someone without statistical knowledge).

Changes: Statistical methods Page 10, line 212-3: addition of the specific Stata command used.

a. The number of proposed variables, in light of a population of 225 subjects, provokes the question of overfitting of the model. This could be addressed if the authors were to show their methods for selection of the clinical variables with their predefined integer and fractional power terms (intrinsic to the fractional polynomial method), and describe in detail the stepwise iterative technique.

Response: The backward elimination process was automated by the software and we have edited the text (line 217) to reflect this. The number of proposed variables was minimised by wrapping the baseline characteristics into a single “score”, then models only included this score plus 17 laboratory parameters which we believe is not excessive. The specific laboratory parameters were selected a priori from a more extensive list, with the aim of avoiding over-fitting the data. Final models only included one or two predictive laboratory parameters (see Table S5) so we feel there is little concern about over-fitting.

Changes: Statistical methods Page 10, line 217: addition of the word “automated” to line 217

b. The resulting model, with iterative summary, needs to be shown even if the primary aim of the study was to evaluate solely the contribution of coagulation tests. The reason is this: Suppose the study involved risk factors for postoperative atrial fibrillation in adults cardiac surgery. If the primary aim involved some medical or surgical intervention, the results would be meaningless (if not undetectable) if the authors did not account for the overwhelming impact of age, and show the magnitude of age (and other clinical factors) on their measured outcomes. Showing the models would also reveal the amount of variability accounted for, some measure of goodness-of-fit, and whether overfitting was a problem. The readership deserves to see these features in the statistical approach.

Response: The models that quantified the associations between the pre-operative characteristics and the primary outcome are displayed in Figures 2 and 3. The final models after automated backwards stepwise selection are shown in Table S5. There are no iterative summaries available in Stata and we believe there is sufficient reporting of the models.

Changes: No changes have been made to the manuscript

c. The authors claim that at the time of study design, evidence for re-sternotomy as a bleeding risk factor was not as strong as it is now. In response, re-sternotomy has been recognized as a strong bleeding risk factor for decades. Re-sternotomy was

identified as a major risk factor by Williams et al in their classic study in 1999 (Anesth Analg 89:57), and many times since then (Gomez et al, Transfus Alt Transfus Med 2002 4:27). Duke's DCRI identified reoperation as a specific risk group in children, and the role of aprotinin in alleviating this risk specifically. This was in 2012, the year before the current study enrollment began. Inclusion of significant clinical risk factors may, again despite what the authors claim, alter the results of the study since accounting for more variability in the outcome often allows the detection of other weaker risk factors. Again, in studies involving postoperative atrial fibrillation, inclusion of strong risk factors, such as age and beta blocker withdrawal, is done so that the impact of weaker risk factors can be detected. This reviewer would like to see either (1) reoperation included in the clinical models (with the models shown), or (2) a more defensible reason why reoperation was not included (it was captured, as the authors mention).

Response: We thank this reviewer for presenting evidence of the importance of sternotomy as a risk factor. We accept this as a fair criticism because in retrospect we gave this insufficient priority in the original study design resulting in its omission from the clinical predictive models.

In our revised manuscript, we included the frequency of reoperation in the description of the clinical characteristics of the cases (table 1) after reinspection of clinical records. However, since this characteristic was not *pre-specified* in our statistical analysis plan we believe that it is inappropriate to repeat the analyses with reoperation included post hoc. We highlight to the reviewer that the main objective of the study was to examine the effect of adding prospective coagulation test results to a baseline clinical predictive model. Omission of reoperation may have slightly reduced the predictive value of the baseline clinical characteristics models, but also the combined models which included the coagulation test results. Therefore, this omission is very unlikely to have altered the difference between the models and the overall conclusion. This point is made in our revised manuscript in the strengths and limitations section discussion, page 17, lines 383-388

Changes: We have made no further changes to the manuscript

e. Table S5 again contains odds ratios less than one for two anti-Xa terms which are inversely related to each other. The interpretation of this is that both high anti-Xa levels and low anti-Xa levels are protective for CCB. Linear or nonlinear, this makes no clinical sense. In addition, there is an odds ratio of 10^{-28} , which is essentially zero, while the same variable raised to the $-3/2$ power has an odds ratio no different from 1 (it should be closer to infinity since the two variables are inversely related). Aside from being implausible, this truly makes one wonder about spurious associations arising from algebraic manipulations (fractional powers) of the data, and whether the fractional polynomial regression method is appropriate here.

Response: The nature of fractional polynomial regression models mean that the most-complex permitted fractional polynomial model is fitted and then simplified as much as possible by the statistical software. Whilst it appears that these two factors are in conflict, the terms would always be fitted together not in isolation, and together best describe the relationship between anti-Xa and the primary outcome. Table S5 presents a transparent summary of the multivariate fractional polynomial models and highlights which laboratory terms are selected as contributing to the final model. We believe the key message to the reader is which terms are selected rather than the final estimates as these are complex to attempt to interpret in isolation.

Changes: No changes to the manuscript

3. (Incorrectly listed as 4 in original critique) Patient population:

a. Again, the authors argue that refinements in clinical prediction would not alter their conclusions regarding the contribution of coagulation testing. See 2c above. The acknowledgement in the limitations regarding additional age classifications is appreciated.

Response: Thank you

b. It should be pointed out that this population, having very few neonates, is missing the segment of the cardiac surgery population most at risk for bleeding complications, so application to populations which have appreciable numbers of neonates may be limited.

Response: We have already highlighted the likely reason why neonates were underrepresented in the study population in the strengths and limitations section of Discussion. To be explicit about the potential effect of this we have inserted a further sentence to this section.

Changes: Discussion page 17, lines 381-383: insertion of the sentence '*This constraint precluded inclusion of neonates in which bleeding is prevalent and prevents generalisation of our findings to this age group*'.

Reviewer #3: No further points raised

Response: Thank you

Reviewer #4: The authors have addressed many of the reviewers' concerns. They have put considerable effort into clarifying the outcome measures employed specifically changing the primary outcome from excessive bleeding (EB) to clinical concern of bleeding (CCB). However, the subjective nature of this outcome measure

remains a major flaw in study design. Furthermore, the generalizability of the results is questionable given the low incidence of significant bleeding (99% of patients received 0-1 units of allogenic blood products), the low number of neonates, and the avoidance of deep hypothermia. Ultimately, the results of this work must be interpreted with caution. While coagulation testing may not be superior to clinical characteristic modeling in the prediction of bleeding, it has been consistently linked to improve outcomes through goal direction of component therapy.

Response: We thank the reviewer for articulating these concerns. We believe that the specific changes requested by reviewer 1 and 2 further clarify the message and that the current manuscript adequately highlights the se points in the improved 'strengths and limitations' section.

Associated Statistical Editor: No additional points

Response: Thank you

Revision Requirements

Please revise your manuscript promptly. Revised manuscripts fare best when the concerns are fresh in the mind of the reviewer. Your revision must be submitted by Dec 02, 2020. You may request a deadline extension if extensive revisions or new experiments are requested by the reviewers.

1. Response to the Reviewers

Please provide a point-by-point response to the Editors' and reviewers' comments and for each comment indicate what changes were made to the manuscript.

Both the responses and changes **must** be submitted in the designated space.

For each comment provide the following three items:

1. The Editor's or Reviewer's comments - separately list each comment
 2. The author(s) response
 3. What Changes were made to the manuscript (and specify the lines) or explain why no changes were made.
2. Confirm that your manuscript conforms to the length requirements found in our Instructions to Authors.
3. Submit in the appropriate box in Editorial Manager a detailed response describing how you have responded to the Editor's and reviewers' comments and defend any changes you have chosen not to make.
4. Submit a marked copy of your original manuscript that clearly identifies the revisions (using bold type) and deletions (using strikethrough) you have made that have resulted in the revised manuscript; this can also be done by using the track changes feature in Microsoft Word. Submit also a revised, nonmarked version. Clearly identify each version by using different file names.
5. Submit the marked and nonmarked versions, and any revised figures or tables via Editorial Manager (jtcvs.editorialmanager.com). The system will arrange them in the necessary order for re-review.
6. Submit your revised manuscript as a revision of the original submission rather than as a new manuscript. Revisions submitted as new manuscripts will be sent back for resubmission.
7. The JTCVS requires that each author complete a conflict of interest disclosure electronically through Editorial Manager. Each author must complete the questionnaire to confirm authorship and to fully disclose all commercial and/or financial relationships. **NEW: JTCVS no longer requires that authors complete PDF disclosure forms. Instead, each author must complete an electronic questionnaire to confirm authorship and fully disclose all commercial and/or financial relations. We will send an email to each author with a link to the questionnaire. In addition, all disclosures MUST be detailed on the title page of**

the manuscript. Processing your manuscript will be delayed until all authors have completed their disclosure questionnaires.

8. Be sure that all figures meet the requirements for print publication. All figures must be in a .tiff or .jpeg format; line art and illustration need to be at 1200 dpi resolution, and photographs must be at 300 dpi resolution. Failure to do this at the revision stage will mean delay in publication if your manuscript is accepted.

In the event that the revisions raise additional concerns, we will take the liberty to have the manuscript re-reviewed.

Thank you for submitting this excellent study to the Journal. We look forward to hearing from you.

Regards,

Richard D. Weisel, MD, Editor

Robert D.B. Jaquiss, MD, Associate Editor

David Zurakowski, MSc, PhD, Associate Statistical Editor

S. Ram Kumar Subramanyan MD, PhD, Seminars Editor

The Journal of Thoracic and Cardiovascular Surgery
American Association for Thoracic Surgery
800 Cummings Center, Suite 350-V
Beverly, MA 01915
Telephone: 978-252-2200 Ext. 549
E-mail: jtcvs@aats.org

Prediction of bleeding in paediatric cardiac surgery using clinical

characteristics and prospective coagulation test results

Jessica M Harris BSc, MSc, PhD¹, Karen Sheehan MSc², Chris A Rogers BSc, PhD¹, Tim Murphy MBBS FRCA², Massimo Caputo MD MCh^{2,3,4}, Andrew D Mumford MB ChB PhD⁵

1. Bristol Trials Centre, Faculty of Health Sciences, University of Bristol, Bristol, UK.
2. Department of Paediatric Cardiac Surgery, Bristol Royal Hospital for Children, University Hospitals Bristol, Bristol, UK.
3. Bristol Heart Institute, University Hospitals Bristol, Bristol, UK.
4. Department of Paediatric Cardiac Surgery, School of Translational Sciences, University of Bristol, Bristol, UK.
5. Department of Haematology, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Conflicts of Interest: The authors declare no relevant conflicts of interest

Funding statement: The study was supported by the UK National Institute for Health Research through the Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol, and the British Heart Foundation.

Corresponding author: Professor Andrew Mumford, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. Email a.mumford@bristol.ac.uk

Clinical trial registration: ISRCTN55439761

NHS Research Ethics Committee: approval 13/LO/0504 (2013)

Key Words: Coagulation testing; Paediatric Cardiac Surgery; Bleeding; Predictive models; Coagulopathy

Manuscript length: Total 3498 words; Abstract 250 words; Figures 3; Tables 4; Supplementary file 1; References 34

17 GLOSSARY OF ABBREVIATIONS

Anti-Xa	Anti-Xa heparin activity
APTT	Activated partial thromboplastin time
ASD	Atrial septal defect
AUC	Multiplate test area under curve
AV	Atrioventricular
AVSD	Atrioventricular Septal Defect
CCB	Clinical concern about bleeding
CPB	cardiopulmonary bypass
CT	ROTEM clot time
ETP	Endogenous thrombin potential
FIB	Clauss fibrinogen activity
MCF	ROTEM maximum clot firmness
ML	ROTEM maximum clot lysis
MUF	Modified ultra-filtration
NHS	National Health Service
PAPVD	Partial Anomalous Pulmonary Venous drainage
PLT	Platelet count
PT	Prothrombin time
RACHS-1	Risk adjustment in Congenital Heart Surgery-1
rFVIIa	Recombinant activated factor VII
TAPVD	Total Anomalous Pulmonary Venous Drainage
VSD	Ventricular septal defect

18

19

CENTRAL PICTURE

CENTRAL PICTURE LEGEND: Bleeding prediction models improves little after including prospective coagulation test results.

CENTRAL MESSAGE: Prospective coagulation testing offers little additional benefit to prediction of excessive bleeding in children undergoing cardiac surgery when compared to prediction using clinical characteristics alone.

PERSPECTIVE STATEMENT: Excessive bleeding because of coagulopathy causes adverse outcomes in children having cardiac surgery. Rapid coagulation testing to help selection of treatments for bleeding improves outcomes but has uncertain utility for predicting whether bleeding will occur. We show that prospective coagulation testing has little additional value compared to prediction using the clinical characteristics of children alone.

ABSTRACT

Objective: Bleeding caused by coagulopathy is common in children undergoing cardiac surgery and causes adverse outcomes. Coagulation testing assists selection of treatments to stop bleeding but has an uncertain role for predicting bleeding. We aimed to evaluate how well prospective coagulation testing predicted excessive bleeding during and after cardiac surgery compared to prediction using clinical characteristics alone.

Methods: A single centre, prospective cohort study in children having a range of cardiac surgery procedures with coagulation testing at anaesthetic induction and immediately after cardio-pulmonary bypass. The primary outcome was clinical concern about bleeding (CCB), a composite of either administration of pro-haemostatic treatments in response to bleeding or a high chest drain volume after surgery.

Results: In 225 children, CCB occurred in 26 (12%) during surgery and in 68 (30%) after surgery. Multivariable fractional polynomial models using the clinical characteristics of the children alone predicted CCB during surgery (*c-statistic* 0.64; 95% confidence interval 0.53, 0.76) and after surgery (0.74; 0.67, 0.82). Incorporating coagulation test results into these models improved prediction (*c-statistics* 0.79; 0.70, 0.87 and 0.80; 0.74, 0.87 respectively). However, this increased the overall proportion of children classified correctly as CCB or not CCB during surgery by only 0.9% and after surgery by only 0.4%. Incorporating coagulation test results into predictive models had no effect on prediction of blood transfusion or post-operative complications.

Conclusions: Prospective coagulation testing marginally improves prediction of CCB during and after cardiac surgery but the clinical impact of this is small when compared to prediction using clinical characteristics.

INTRODUCTION

Microvascular bleeding caused by coagulopathy and blood transfusion in response to bleeding are common after cardiac surgery in children^{1,2} and are independent predictors of morbidity and mortality.^{3,4} Coagulopathy is typically complex and may include reduced levels or reduced function of platelets, coagulation factors or fibrinogen.⁵ These changes may relate to the age of children, underlying cardiac disease or medication before cardiac surgery^{6,7} or to interventions that occur during surgery, particularly heparin anticoagulation, hypothermia and cardiopulmonary bypass (CPB).⁸⁻¹⁰

Coagulation testing using point-of-care viscoelastometry or rapid platelet function testing detects major components of coagulopathy during cardiac surgery in children.^{7,11,12} In retrospective case control studies, viscoelastometry-assisted selection of treatments reduced blood component use in children who developed excessive bleeding.^{13,14} In a randomised controlled trial of children with excessive bleeding, viscoelastometry resulted in less bleeding and blood transfusion.¹⁵ Further support for the utility of blood management algorithms that include diagnostic coagulation test results has been reproduced in other recent studies¹⁶⁻¹⁸.

An alternative strategy is to perform prospective testing before bleeding occurs, potentially enabling preventative treatments in children at greatest risk or the pre-ordering of treatments for immediate administration if bleeding starts. However, most previous studies of prospective testing for prediction of bleeding have evaluated only small patient cohorts using limited repertoires of coagulation tests and have yielded inconsistent findings.^{15,19-21} In studies of larger cohorts of children, predictive models for excessive bleeding have

incorporated both coagulation test results and the clinical characteristics of children, thereby obscuring the utility of coagulation testing alone.^{1, 22, 23}

We performed the Detection of Coagulopathy in Paediatric Heart Surgery (DECISION) study to investigate how well prospective coagulation testing predicts excessive bleeding in children undergoing cardiac surgery, compared with prediction using clinical characteristics alone.

METHODS

Study design and patients

The DECISION study was a prospective single-centre observational cohort study conducted at University Hospitals NHS Foundation Trust between May 2013 and April 2015 in accordance with the Declaration of Helsinki and United Kingdom NHS Research Ethics Committee approval 13/LO/0504.

Children were eligible if they were aged 16 years or younger, had a body weight of more than 2.5 Kg and were listed for any non-emergency cardiac surgery procedure requiring CPB.

Children were ineligible if undergoing isolated ostium secundum ASD repair in which bleeding risk is very low, or if they required emergency cardiac surgery. Parental consent was obtained for children younger than 16 years. Direct consent was obtained for children aged 16 years. A detailed study protocol is reported elsewhere.²⁴

Surgical and blood management procedures

All the children were managed according to a standard institutional anaesthetic protocol described previously²⁵. A bolus dose of heparin 300-400 units/Kg was administered before

aortic cannulation with additional doses of 100 units/kg to maintain an activated clotting time (ACT) >400 s. Protamine (10 mg/1000 units of heparin administered) was given at the end of CPB with additional boluses of 2-4 mg given sequentially until the ACT was <150s. Protamine was also administered after return of pump blood (5mg/100ml) which was also ultra-filtrated for all neonates and children <10Kg. Tranexamic acid (30-80 mg/kg total dose) and cell-savers for redo procedures and for complex aortic valve procedures were used according to the discretion of the anaesthesiologist. The administration of tranexamic acid and protamine as part of this standard protocol was planned before surgery and not given in response to abnormal bleeding. These interventions were classified as *pre-planned preventative treatments*.

Anesthesiologists also administered pro-haemostatic treatments hereafter termed *treatments in response to bleeding* in two circumstances: i.) during surgery if there was excessive chest cavity bleeding unattributable to a surgical bleeding point, or ii.) after surgery if there was concern about the rate of blood loss from chest drains or if there was indirect evidence of bleeding such as unexplained hypotension or anaemia. These treatments were usually selected using thromboelastography or ACT tests performed in the operating theatre of intensive care unit but in some emergency circumstances, treatments were selected empirically based on clinical circumstances. The results of the coagulation tests performed in the study were unavailable to clinicians and did not influence the choice of whether or not to administer pro-haemostatic treatments.

The clinical teams recorded administration and the indication for any pro-haemostatic treatment (fresh frozen plasma, cryoprecipitate, platelet concentrates, or additional protamine given after initial correction of the ACT at the end of CPB) that was administered between

anaesthetic induction and the first 12 hours after insertion of chest drains. Case report forms and where necessary the primary anaesthetic records were subsequently inspected by senior clinical members of the research team for all interventions recorded as *treatments in response to bleeding* to confirm correct classification.

Outcomes

The primary outcome was clinical concern about bleeding (CCB) defined as either of the following events in the interval between the start of surgery and 12 hours after insertion of chest drains: i.) administration of any pro-haemostatic treatment in response to bleeding, or, ii.) a chest drain volume of either >5ml/Kg /hr in any 1 hour interval or >3ml/kg/hr for 3 consecutive hours²⁶ (relevant for the post-operative interval only).

Pro-haemostatic treatments in response to bleeding were included in the primary outcome since it was not otherwise possible to capture excessive bleeding that occurred before the insertion of chest drains or when excessive bleeding was detected and treated after chest drain insertion before reaching the pre-designated volume threshold. Pre-planned preventative pro-haemostatic treatments were not included in the primary outcome because they were administered to children before any excessive bleeding occurred and were planned before surgery according to the blood management protocol.

The secondary outcomes were administration of any blood transfusion given within 12 hours of surgery or post-operative complications (Supplementary table S1). Post-operative complications were classified as serious if they were judged by the treating clinicians as likely to have increased the length of hospital stay, to have been life threatening or if the complication caused persistent or significant disability or resulted in death.

169

170 **Blood samples and laboratory testing**

171 A pre-operative blood sample was taken after anaesthetic induction but before
172 anticoagulation with heparin. A post-CPB blood sample was taken after completion of
173 protamine reversal of heparin anticoagulation at the end of CPB, but before the return of
174 pump blood, insertion of chest drains and chest closure. Both blood samples were analysed
175 using Sysmex XN and CS-2100 series blood count and coagulation analysers (Sysmex Corp.
176 Kobe, Japan), a Multiplate platelet function analyser (Roche Diagnostics, Switzerland) and a
177 ROTEM delta thromboelastometer (TEM International GmbH, Germany). A total of 17 test
178 results or derived parameters were pre-specified as potential predictors of the primary
179 outcome. The blood test results were unavailable to the clinicians responsible for the care of
180 the patients.

181

182 **Selection of clinical predictors**

183 The *baseline characteristics* of the children that were pre-specified as potential predictors of
184 CCB were those characteristics known to the surgical teams at the start of surgery. These
185 comprised patient age (0-28 days old *vs* older), sex, RACHS-1 category of the planned
186 procedure²⁷ weight-for-age z-score using the British 1990 Growth Reference data, pre-
187 operative anti-thrombotic medication (aspirin, warfarin or other anticoagulants at admission
188 for surgery), pre-operative prostin, and pre-operative haemoglobin level. The *surgical*
189 *characteristics* were potential predictors only known to the surgical teams at the end of
190 cardiac surgery and comprised total CPB time, aortic cross-clamp time, minimum
191 temperature during CPB, use of cell saver, return of pump blood, blood transfusion during
192 surgery and the presence of CCB during surgery.

193

Statistical analysis

In order to evaluate how well coagulation test results predicted CCB during surgery and after surgery, three sets of predictive models were generated: i.) pre-operative test results versus CCB during surgery; ii.) post-CPB test results versus CCB after surgery, and, iii.) pre-operative test results versus CCB after surgery. For each set of models, the association between the coagulation test results and CCB was assessed alongside the association between the clinical characteristics and CCB. Finally, both the clinical characteristics and coagulation test results were assessed in the same model, to test whether there was improvement in model fit.

The analysis population for the models of CCB during surgery was all children who had collection of the pre-operative blood sample and for the models of CCB after surgery was all children who had collection of the post-CPB blood sample. Multiple imputation methods using predictive mean matching and ten imputations was used for children with missing clinical characteristics or coagulation test results. Multivariable fractional polynomial models were used to allow for non-linearity of terms ²⁸ [using the *mfpmi* command in Stata, which builds multivariable fractional polynomial models in multiply imputed data](#). In addition to adjustment for the pre-specified predictors of CCB, the models were additionally adjusted for whether the patient was in the intervention arm of either of two concurrent trials (Thermic-2 ISRCTN81773762: (22 children) and OXIC-2 ISRCTN13467772: 11 children). In the models that included the coagulation test results, [automated](#) backward elimination was used to identify the test results that contributed significantly to the final model using cut-off of 0.05 in most cases, but this was increased to 0.10 if this did not result in the selection of terms. The overall effectiveness of the models in predicting CCB was reported using the *c-statistic* with 95% confidence intervals (95% CI) with differences between these tested using

the DeLong method.²⁹ The percentage of children correctly classified in each model has having CCB or no CCB was calculated using the non-imputed data. These analyses were repeated for assessing the associations with the secondary outcomes.

RESULTS

Study population

Of the 441 children who were assessed for eligibility, 75 were ineligible and 58 were eligible but were not approached for other reasons (Figure 1). Of the 308 children who were approached, consent to participate was obtained for 242 (79%). The overall analysis population for which data were collected was 225 children. Coagulation test results from all 225 children were included in the CCB during surgery models. For the CCB after surgery models, results from three children were excluded because the post-CPB blood samples could not be collected at the correct time. Imputation of at least one missing test result or clinical characteristic was required for seven of 225 (3%) children for the CCB during surgery models and for 20 of 222 (9%) children for the CCB after surgery models.

Baseline and surgical clinical characteristics

The clinical characteristics of the overall study group are shown in Table 1 and in Supplementary tables S2 and S3. The median age of the children was 1.3 years (range 2 days to 16.9 years). A total of 119 the children (53% of the overall analysis population) were male. The most common surgical procedures were bidirectional Glenn shunts or the Fontan procedure (14%) and repair of tetralogy of Fallot (13%). Most procedures had RACHS-1 category of two or three (88%). For 33% of procedures, the children had had at least one previous cardiac surgery procedure.

Of the 225 children in the overall analysis population, 26 (12%) had CCB during surgery, because they received a pro-haemostatic treatment in response to bleeding. A total of 68 (30%) had CCB after surgery of which 53 had a pro-haemostatic treatment in response to bleeding without having high chest-drain loss (Table 2). Sixty children (27%) had the secondary outcome of any blood transfusion after surgery, 99 (44%) any post-CPB complication and 62 (28%) any serious post-CPB complication (Table 2).

Coagulation test results

The prospective coagulation test results from the overall analysis population are shown in Table 3, in Supplementary Tables S2 and S4 and Figures S1 and S2. The main differences in the post-CPB results compared to the pre-operative results were reduced platelet count and platelet function (reduced PLT and reduced AUCs for the Multiplate tests), dysfunctional coagulation pathway (prolonged PT or APTT and reduced ETP), reduced fibrinogen (reduced FIB) and the persistent heparin after protamine reversal (increased anti-Xa). These changes were reflected in the ROTEM results which showed higher CT and lower MCF (EXTEM and INTEM) and lower MCF (FIBTEM) in the post-CPB samples, compared to the pre-operative samples (Table 3).

Prediction of clinical concern about bleeding during surgery

When considered individually, none of the baseline characteristics were associated with a statistically significant difference in odds ratio of CCB during surgery (Figure 2A), but when incorporated into a model they enabled prediction of CCB during surgery with a *c-statistic* of 0.64 (95% confidence interval 0.53, 0.76). The alternative model incorporating the pre-operative coagulation test results alone enabled prediction of CCB during surgery with a *c-statistic* of 0.65 (0.56, 0.76). A combined model that incorporated both the baseline

characteristics and the pre-operative coagulation test results had a *c-statistic* of 0.79 (0.70, 0.87), representing a statistically significant ($p=0.01$) improvement in model fit (Figure 2B). However, the number of children correctly predicted to have either CCB or no CCB during surgery was 198 with the baseline characteristics alone model and 200 with combined model, corresponding to an uplift in correct classification in only 0.9% of children.

Prediction of clinical concern about bleeding after surgery

The baseline characteristics female sex, higher RACHS1 category, and the surgical characteristics increased total CPB time and no use of cell saver were independent predictors of CCB after surgery (Figure 3A). The model incorporating the baseline and surgical characteristics enabled prediction of CCB after surgery with a *c-statistic* of 0.74 (0.67, 0.82). The model incorporating only the post-CPB coagulation test results enabled prediction of CCB after surgery with a *c-statistic* of 0.59 (0.51, 0.68). The combined model that incorporated the baseline and surgical characteristics and also the post-CPB coagulation test results had a *c-statistic* of 0.80 (0.74, 0.87), representing a statistically significant ($p=0.02$) improvement in model fit (Figure 3B). The number of children correctly predicted to have CCB or no CCB after surgery was 163 with the baseline and surgical characteristics alone model and 164 children with the combined model, corresponding to an uplift in correct classification in only 0.4% of children. The final fitted combined models are shown in Supplementary Table S5.

A similar analysis was performed to assess whether CCB after surgery could be predicted using only the baseline characteristics of the children and the pre-operative coagulation test results. Similar to the previous findings, CCB after surgery could be predicted using a model incorporating baseline characteristics alone (*c-statistic* 0.72 CI 0.64, 0.79), but this was not

improved by incorporating the pre-operative coagulation test results (*c-statistic* 0.74 CI 0.66, 0.81; test of equality $p=0.25$) (Supplementary Figures S3 and S4).

Prediction of the secondary outcomes

The clinical characteristics of the children and the post-CPB coagulation test results according to presence or absence of each secondary outcomes are reported in Supplementary tables S6 and S7. For all of the secondary outcomes, the predictive models incorporating the clinical characteristics alone had higher *c-statistics* than the corresponding models incorporating the post-CPB coagulation test results (Table 4). There was no further increase in *c-statistic* after combining the clinical and test result models.

DISCUSSION

In this prospective study of 225 children having a wide range of cardiac surgery procedures, we evaluated how well prospective coagulation testing at anaesthetic induction or just after CPB improved the prediction of CCB, when compared to prediction using clinical characteristics alone. The main finding was that the predictive models that incorporated clinical characteristics were improved after coagulation test results were included in the models. However, this resulted in an increase in correct prediction in only 0.9% of children for CCB during surgery and 0.4% of children for CCB after surgery. Incorporation of prospective coagulation test results did not improve prediction of blood transfusion or post-CPB complications (Figure 4).

Predictive models using clinical characteristics

We found a trend towards more frequent CCB in younger children and those receiving anti-thrombotic drugs at the point of admission for surgery, similar to previously reports.^{1, 22} CCB after surgery was associated with more complex planned surgery (high RACHS-1 score),

increased total CPB time and no use of cell saver, which also reproduces previous findings.^{1, 15, 22, 23} The association between CCB after surgery and increased duration of CPB supports previous observations that activation and consumption of platelets, clotting factors and fibrinogen by the extracorporeal CPB circuit results in significant coagulopathy.⁵ The association between CCB after surgery and no use of cell saver likely reflects that without a cell saver, blood volume is typically restored using crystalloid or red cell blood transfusion which have no haemostatic activity and have previously been shown to increase pro-haemostatic treatments when compared to cell saver blood.³⁰

Contribution of prospective coagulation test results

The coagulation test results showed complex abnormalities in platelet number and function, coagulation pathway function and in fibrinogen activity that frequently co-existed in the same blood sample, similar to previous studies.⁸⁻¹⁰ Although there were abnormalities in some pre-operative blood test results, abnormal results were more frequent in the post-CPB blood samples, indicating development of coagulopathy during surgery and consistent with the known effects of CPB and interventions such as heparin anticoagulation.⁵

Coagulation test results consistently associated with bleeding in previous studies including low platelet count²², viscoelastometric clot strength reflecting the contribution of both platelet and fibrinogen to haemostasis (ROTEM MCF or TEG MA tests)^{15, 19, 22} or low fibrinogen (ROTEM FIBTEM MCF or FIB).^{15, 23} were included in the test panel evaluated in our study. However, uniquely in our study we revealed that the additional value of using these and other test results for prediction of CCB is very low if prediction is already performed using clinical characteristics alone. This conclusion was the same for the secondary outcomes of blood transfusion or post-operative complications which are potential

consequences of bleeding.^{3, 4, 31, 32} This suggests that the main underlying causes of coagulopathy were reflected in the clinical characteristics of the cases which were thereby sufficient to drive the predictive models and that demonstration of an abnormal results in prospective coagulation tests provided little clinically useful information.

Strengths and weaknesses

The main strength of the DECISION study was the features of the study design that minimised the risk of bias: (i) the study enrolled unselected children having a wide range of procedures, (ii) 79% of the eligible children who were approached were enrolled into the study and had data collected, and (iii) the coagulation tests were performed using standardised methodology in a remote laboratory so that the results could not influence the study outcomes.

It is also a strength that the primary outcome was a composite of high blood loss observed from chest drains in the post-operative period but also the administration of any pro-haemostatic product for the treatment of bleeding. This pragmatic definition enabled identification of children with excessive bleeding during surgery before chest drain insertion, but also after surgery when pro-haemostatic treatments early in the course of bleeding frequently arrest bleeding before the threshold values for chest drain blood loss are reached. Although this approach is likely to have captured all episodes of excessive bleeding, it is possible that some pro-haemostatic treatments may have been given without evidence of excessive bleeding resulting in incorrect classification of children as having reached the primary outcome. Conversely a very small number of children may have received treatments in response to bleeding that were not documented as such. We minimised the impact of these potential errors by ensuring that a contemporaneous record was made of the indication for

each pro-haemostatic treatment and by reviewing the clinical record to ensure that these were correctly classified.

It is a potential weakness of the study that since it was conducted in a single centre the findings may not be generalizable to other centres. However, the characteristics of the children were similar to those in other predictive modelling studies^{22, 23} and to children at other Paediatric cardiac surgery centres³³, with the exception that the number of neonates enrolled to our study was lower. This is a likely consequence of exclusion of patients with body weight <2.5 Kg, which was an ethical constraint to minimise the impact of large blood samples needed for comprehensive coagulation testing. This precluded inclusion of neonates in which bleeding is prevalent and prevents generalisation of our findings to this age group.

Incorporation of more recently validated procedural complexity scores such as EACTS STAT instead of RACHS-1 and including repeat sternotomy and more detailed age classifications as terms may potentially have improved performance of the clinical characteristics models. However, these measures would have been unlikely to influence the impact of including coagulation test results to these models, which was the main subject of study.

Clinical impact of the study findings

There is now abundant evidence that incorporation of coagulation test results into blood management algorithms assists selection of targeted pro-haemostatic treatments and reduces blood component use.³⁴ In this study, we evaluated the utility of prospective coagulation testing to predict excessive bleeding. Our findings support the use of clinical characteristics that are readily available either before surgery or during the course of surgery to assist prediction of bleeding. However, our findings do not currently support prospective coagulation testing to improve prediction if clinical characteristics are already considered.

REFERENCES

- [1] Williams GD, Bratton SL, Ramamoorthy C: Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. *Anesth Analg* 1999, 89:57-64.
- [2] Keung CY, Smith KR, Savoia HF, Davidson AJ: An audit of transfusion of red blood cell units in pediatric anesthesia. *Paediatr Anaesth* 2009, 19:320-8.
- [3] Wolf MJ, Maher KO, Kanter KR, Kogon BE, Guzzetta NA, Mahle WT: Early postoperative bleeding is independently associated with increased surgical mortality in infants after cardiopulmonary bypass. *J Thorac Cardiovasc Surg* 2014, 148:631-6 e1.
- [4] Guzzetta NA, Allen NN, Wilson EC, Foster GS, Ehrlich AC, Miller BE: Excessive postoperative bleeding and outcomes in neonates undergoing cardiopulmonary bypass. *Anesth Analg* 2015, 120:405-10.
- [5] Paparella D, Brister SJ, Buchanan MR: Coagulation disorders of cardiopulmonary bypass: a review. *Intensive Care Med* 2004, 30:1873-81.
- [6] Toulon P, Berruyer M, Brionne-Francois M, Grand F, Lasne D, Telion C, Arcizet J, Giacomello R, De Pooter N: Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges. *Thromb Haemost* 2016, 116:9-16.
- [7] Miller BE, Guzzetta NA, Tosone SR, Miller JL, Flunker AR, Silvey EM, Levy JH: Tissue factor-activated thromboelastograms in children undergoing cardiac surgery: baseline values and comparisons. *Anesth Analg* 2003, 97:1289-93.
- [8] Romlin BS, Soderlund F, Wahlander H, Nilsson B, Baghaei F, Jeppsson A: Platelet count and function in paediatric cardiac surgery: a prospective observational study. *Br J Anaesth* 2014, 113:847-54.

418 [9] Faraoni D, Willems A, Savan V, Demanet H, De Ville A, Van der Linden P: Plasma
419 fibrinogen concentration is correlated with postoperative blood loss in children undergoing
420 cardiac surgery. A retrospective review. *Eur J Anaesthesiol* 2014, 31:317-26.

421 [10] Mossad EB, Machado S, Apostolakis J: Bleeding following deep hypothermia and
422 circulatory arrest in children. *Semin Cardiothorac Vasc Anesth* 2007, 11:34-46.

423 [11] Romlin BS, Soderlund F, Wahlander H, Hallhagen S, Wessman C, Baghaei F, Jeppsson
424 A: Perioperative monitoring of platelet function in paediatric cardiac surgery by
425 thromboelastometry, or platelet aggregometry? *Br J Anaesth* 2016, 116:822-8.

426 [12] Rizza A, Ricci Z, Pezzella C, Favia I, Di Felice G, Ranucci M, Cogo P: Kaolin-activated
427 thromboelastography and standard coagulation assays in cyanotic and acyanotic infants
428 undergoing complex cardiac surgery: a prospective cohort study. *Paediatr Anaesth* 2017,
429 27:170-80.

430 [13] Romlin BS, Wahlander H, Berggren H, Synnergren M, Baghaei F, Nilsson K, Jeppsson
431 A: Intraoperative thromboelastometry is associated with reduced transfusion prevalence in
432 pediatric cardiac surgery. *Anesth Analg* 2011, 112:30-6.

433 [14] Kane LC, Woodward CS, Husain SA, Frei-Jones MJ: Thromboelastography--does it
434 impact blood component transfusion in pediatric heart surgery? *J Surg Res* 2016, 200:21-7.

435 [15] Nakayama Y, Nakajima Y, Tanaka KA, Sessler DI, Maeda S, Iida J, Ogawa S, Mizobe
436 T: Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and
437 red cell transfusion after paediatric cardiac surgery. *Br J Anaesth* 2015, 114:91-102.

438 [16] Faraoni D, Willems A, Romlin BS, Belisle S, Van der Linden P: Development of a
439 specific algorithm to guide haemostatic therapy in children undergoing cardiac surgery: a
440 single-centre retrospective study. *Eur J Anaesthesiol* 2015, 32:320-9.

441 [17] Timpa JG, O'Meara LC, Goldberg KG, Phillips JP, Crawford JH, Jackson KW, Alten
442 JA: Implementation of a Multidisciplinary Bleeding and Transfusion Protocol Significantly

443 Decreases Perioperative Blood Product Utilization and Improves Some Bleeding Outcomes. J
 444 Extra Corpor Technol 2016, 48:11-8.

445 [18] Whitney G, Daves S, Hughes A, Watkins S, Woods M, Kreger M, Marincola P, Chocron
 446 I, Donahue B: Implementation of a transfusion algorithm to reduce blood product utilization
 447 in pediatric cardiac surgery. Paediatr Anaesth 2013, 23:639-46.

448 [19] Moganasundram S, Hunt BJ, Sykes K, Holton F, Parmar K, Durward A, Murdoch IA,
 449 Austin C, Anderson D, Tibby SM: The relationship among thromboelastography, hemostatic
 450 variables, and bleeding after cardiopulmonary bypass surgery in children. Anesth Analg
 451 2010, 110:995-1002.

452 [20] Hayashi T, Sakurai Y, Fukuda K, Yada K, Ogiwara K, Matsumoto T, Yoshizawa H,
 453 Takahashi Y, Yoshikawa Y, Hayata Y, Taniguchi S, Shima M: Correlations between global
 454 clotting function tests, duration of operation, and postoperative chest tube drainage in
 455 pediatric cardiac surgery. Paediatr Anaesth 2011, 21:865-71.

456 [21] Andreasen JB, Hvas AM, Christiansen K, Ravn HB: Can RoTEM(R) analysis be applied
 457 for haemostatic monitoring in paediatric congenital heart surgery? Cardiol Young 2011,
 458 21:684-91.

459 [22] Williams GD, Bratton SL, Riley EC, Ramamoorthy C: Coagulation tests during
 460 cardiopulmonary bypass correlate with blood loss in children undergoing cardiac surgery. J
 461 Cardiothorac Vasc Anesth 1999, 13:398-404.

462 [23] Miller BE, Mochizuki T, Levy JH, Bailey JM, Tosone SR, Tam VK, Kanter KR:
 463 Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth
 464 Analg 1997, 85:1196-202.

465 [24] Underwood W, Rogers CA, Plummer Z, B CR, Caputo M, Murphy P, Sheehan K, Harris
 466 J, Culliford L, Mumford A: Detection of coagulopathy in paediatric heart surgery
 467 [DECISION study]: study protocol. BMC Hematol 2015, 15:11.

468 [25] Caputo M, Patel N, Angelini GD, de Siena P, Stoica S, Parry AJ, Rogers CA: Effect of
469 normothermic cardiopulmonary bypass on renal injury in pediatric cardiac surgery: a
470 randomized controlled trial. *J Thorac Cardiovasc Surg* 2011, 142:1114-21, 21 e1-2.

471 [26] Pekelharing J, Furck A, Banya W, Macrae D, Davidson SJ: Comparison between
472 thromboelastography and conventional coagulation tests after cardiopulmonary bypass
473 surgery in the paediatric intensive care unit. *Int J Lab Hematol* 2014, 36:465-71.

474 [27] Jenkins KJ, Gauvreau K: Center-specific differences in mortality: preliminary analyses
475 using the Risk Adjustment in Congenital Heart Surgery (RACHS-1) method. *J Thorac*
476 *Cardiovasc Surg* 2002, 124:97-104.

477 [28] Zhang Z: Multivariable fractional polynomial method for regression model. *Ann Transl*
478 *Med* 2016, 4:174.

479 [29] DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more
480 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*
481 1988, 44:837-45.

482 [30] Cholette JM, Powers KS, Alfieri GM, Angona R, Henrichs KF, Masel D, Swartz MF,
483 Daugherty LE, Belmont K, Blumberg N: Transfusion of cell saver salvaged blood in neonates
484 and infants undergoing open heart surgery significantly reduces RBC and coagulant product
485 transfusions and donor exposures: results of a prospective, randomized, clinical trial. *Pediatr*
486 *Crit Care Med* 2013, 14:137-47.

487 [31] Salvin JW, Scheurer MA, Laussen PC, Wypij D, Polito A, Bacha EA, Pigula FA,
488 McGowan FX, Costello JM, Thiagarajan RR: Blood transfusion after pediatric cardiac
489 surgery is associated with prolonged hospital stay. *Ann Thorac Surg* 2011, 91:204-10.

490 [32] Iyengar A, Scipione CN, Sheth P, Ohye RG, Riegger L, Bove EL, Devaney EJ, Hirsch-
491 Romano JC: Association of complications with blood transfusions in pediatric cardiac
492 surgery patients. *Ann Thorac Surg* 2013, 96:910-6.

[33] https://web.nicor.org.uk/_80257061003D4478.nsf/vwContent/home?OpenDocument.

[34] Machovec KA, Jooste EH: Pediatric Transfusion Algorithms: Coming to a Cardiac Operating Room Near You. J Cardiothorac Vasc Anesth 2019, 33:2017-29.

ACKNOWLEDGEMENTS: This study was funded by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. This study was designed and delivered in collaboration with the Clinical Trials and Evaluation Unit, Bristol Trials Centre, a UKCRC registered clinical trials unit, which is in receipt of NIHR CTU support funding. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The British Heart Foundation provided additional support. We acknowledge the contribution of Dr Zoe Plummer and Wendy Underwood (Clinical Trials Coordinators), Kathy Selway (Paediatric Cardiac Nurse Specialist) and Mary Walker (research assistant) to the delivery of this study.

Figure 1: Flow of study participants. The flow chart indicates the number of children who were assessed for eligibility, approached to participate, consented to join the study and the number for which complete study datasets were collected (white boxes). The gray boxes indicate the reasons why some children who were assessed for eligibility were not part of the analysis population.

Figure 2: Prediction of excessive bleeding during surgery. A. Associations between the baseline clinical characteristics and clinical concern about bleeding (CCB) during surgery presented as adjusted odds ratios with 95% confidence intervals (CI). **B.** Receiver operator characteristic (RoC) curves of the predictive models for CCB during surgery incorporating the baseline clinical characteristics alone and for a combined model that also incorporated the prospective pre-operative coagulation test results. The areas under the curves (c-statistics) indicate better prediction for the combined model. RACHS-1: Risk adjustment in Congenital Heart Surgery-1. The test of equality value indicates evidence of difference between the RoC curves.

Figure 3: Prediction of excessive bleeding after surgery. A. Associations between the baseline and surgical clinical characteristics of the children and clinical concern about bleeding (CCB) after surgery presented as adjusted odds ratios with 95% confidence intervals (CI). **B.** Receiver operator characteristic (RoC) curves of the predictive models for CCB after surgery incorporating the baseline and surgical characteristics alone and for a combined model that also incorporated the prospective post-CPB coagulation test results. The areas under the curves (c-statistics) indicate better prediction for the combined model. RACHS-1: Risk adjustment in Congenital Heart Surgery-1. The test of equality value indicates evidence of difference between the RoC curves.

Prediction of bleeding using clinical characteristics improves little after including coagulation test results

Figure 4: Graphical abstract

This study overview highlights that from a study population of 225 children undergoing a wide range of cardiac surgery procedures, candidate predictors of bleeding were pre-selected from either the clinical characteristics of the children and from the results of a panel of prospective coagulation tests performed at anaesthetic induction and just after the end of cardiopulmonary bypass. The primary outcome was clinical concern about bleeding, a composite endpoint to reflect excessive bleeding. Predictive models were generated using clinical characteristics alone or in combination with prospective coagulation test results. Although including coagulation test results to the models that already included clinical characteristics improved prediction of CCB, the clinical impact expressed as the improvement in the number of children with correct classification was very small.

Prediction of bleeding in paediatric cardiac surgery using clinical characteristics and prospective coagulation test results

Jessica M Harris BSc, MSc, PhD¹, Karen Sheehan MSc², Chris A Rogers BSc, PhD¹, Tim Murphy MBBS FRCA², Massimo Caputo MD MCh^{2,3,4}, Andrew D Mumford MB ChB PhD⁵

1. Bristol Trials Centre, Faculty of Health Sciences, University of Bristol, Bristol, UK.
2. Department of Paediatric Cardiac Surgery, Bristol Royal Hospital for Children, University Hospitals Bristol, Bristol, UK.
3. Bristol Heart Institute, University Hospitals Bristol, Bristol, UK.
4. Department of Paediatric Cardiac Surgery, School of Translational Sciences, University of Bristol, Bristol, UK.
5. Department of Haematology, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Conflicts of Interest: The authors declare no relevant conflicts of interest

Funding statement: The study was supported by the UK National Institute for Health Research through the Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol, and the British Heart Foundation.

Corresponding author: Professor Andrew Mumford, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. Email a.mumford@bristol.ac.uk

Clinical trial registration: ISRCTN55439761

NHS Research Ethics Committee: approval 13/LO/0504 (2013)

Key Words: Coagulation testing; Paediatric Cardiac Surgery; Bleeding; Predictive models; Coagulopathy

Manuscript length: Total 3498 words; Abstract 250 words; Figures 3; Tables 4; Supplementary file 1; References 34

17 GLOSSARY OF ABBREVIATIONS

Anti-Xa	Anti-Xa heparin activity
APTT	Activated partial thromboplastin time
ASD	Atrial septal defect
AUC	Multiplate test area under curve
AV	Atrioventricular
AVSD	Atrioventricular Septal Defect
CCB	Clinical concern about bleeding
CPB	cardiopulmonary bypass
CT	ROTEM clot time
ETP	Endogenous thrombin potential
FIB	Clauss fibrinogen activity
MCF	ROTEM maximum clot firmness
ML	ROTEM maximum clot lysis
MUF	Modified ultra-filtration
NHS	National Health Service
PAPVD	Partial Anomalous Pulmonary Venous drainage
PLT	Platelet count
PT	Prothrombin time
RACHS-1	Risk adjustment in Congenital Heart Surgery-1
rFVIIa	Recombinant activated factor VII
TAPVD	Total Anomalous Pulmonary Venous Drainage
VSD	Ventricular septal defect

18

19

CENTRAL PICTURE

CENTRAL PICTURE LEGEND: Bleeding prediction models improves little after including prospective coagulation test results.

CENTRAL MESSAGE: Prospective coagulation testing offers little additional benefit to prediction of excessive bleeding in children undergoing cardiac surgery when compared to prediction using clinical characteristics alone.

PERSPECTIVE STATEMENT: Excessive bleeding because of coagulopathy causes adverse outcomes in children having cardiac surgery. Rapid coagulation testing to help selection of treatments for bleeding improves outcomes but has uncertain utility for predicting whether bleeding will occur. We show that prospective coagulation testing has little additional value compared to prediction using the clinical characteristics of children alone.

ABSTRACT

Objective: Bleeding caused by coagulopathy is common in children undergoing cardiac surgery and causes adverse outcomes. Coagulation testing assists selection of treatments to stop bleeding but has an uncertain role for predicting bleeding. We aimed to evaluate how well prospective coagulation testing predicted excessive bleeding during and after cardiac surgery compared to prediction using clinical characteristics alone.

Methods: A single centre, prospective cohort study in children having a range of cardiac surgery procedures with coagulation testing at anaesthetic induction and immediately after cardio-pulmonary bypass. The primary outcome was clinical concern about bleeding (CCB), a composite of either administration of pro-haemostatic treatments in response to bleeding or a high chest drain volume after surgery.

Results: In 225 children, CCB occurred in 26 (12%) during surgery and in 68 (30%) after surgery. Multivariable fractional polynomial models using the clinical characteristics of the children alone predicted CCB during surgery (*c-statistic* 0.64; 95% confidence interval 0.53, 0.76) and after surgery (0.74; 0.67, 0.82). Incorporating coagulation test results into these models improved prediction (*c-statistics* 0.79; 0.70, 0.87 and 0.80; 0.74, 0.87 respectively). However, this increased the overall proportion of children classified correctly as CCB or not CCB during surgery by only 0.9% and after surgery by only 0.4%. Incorporating coagulation test results into predictive models had no effect on prediction of blood transfusion or post-operative complications.

Conclusions: Prospective coagulation testing marginally improves prediction of CCB during and after cardiac surgery but the clinical impact of this is small when compared to prediction using clinical characteristics.

INTRODUCTION

Microvascular bleeding caused by coagulopathy and blood transfusion in response to bleeding are common after cardiac surgery in children^{1,2} and are independent predictors of morbidity and mortality.^{3,4} Coagulopathy is typically complex and may include reduced levels or reduced function of platelets, coagulation factors or fibrinogen.⁵ These changes may relate to the age of children, underlying cardiac disease or medication before cardiac surgery^{6,7} or to interventions that occur during surgery, particularly heparin anticoagulation, hypothermia and cardiopulmonary bypass (CPB).⁸⁻¹⁰

Coagulation testing using point-of-care viscoelastometry or rapid platelet function testing detects major components of coagulopathy during cardiac surgery in children.^{7,11,12} In retrospective case control studies, viscoelastometry-assisted selection of treatments reduced blood component use in children who developed excessive bleeding.^{13,14} In a randomised controlled trial of children with excessive bleeding, viscoelastometry resulted in less bleeding and blood transfusion.¹⁵ Further support for the utility of blood management algorithms that include diagnostic coagulation test results has been reproduced in other recent studies¹⁶⁻¹⁸.

An alternative strategy is to perform prospective testing before bleeding occurs, potentially enabling preventative treatments in children at greatest risk or the pre-ordering of treatments for immediate administration if bleeding starts. However, most previous studies of prospective testing for prediction of bleeding have evaluated only small patient cohorts using limited repertoires of coagulation tests and have yielded inconsistent findings.^{15,19-21} In studies of larger cohorts of children, predictive models for excessive bleeding have

incorporated both coagulation test results and the clinical characteristics of children, thereby obscuring the utility of coagulation testing alone.^{1, 22, 23}

We performed the Detection of Coagulopathy in Paediatric Heart Surgery (DECISION) study to investigate how well prospective coagulation testing predicts excessive bleeding in children undergoing cardiac surgery, compared with prediction using clinical characteristics alone.

METHODS

Study design and patients

The DECISION study was a prospective single-centre observational cohort study conducted at University Hospitals NHS Foundation Trust between May 2013 and April 2015 in accordance with the Declaration of Helsinki and United Kingdom NHS Research Ethics Committee approval 13/LO/0504.

Children were eligible if they were aged 16 years or younger, had a body weight of more than 2.5 Kg and were listed for any non-emergency cardiac surgery procedure requiring CPB.

Children were ineligible if undergoing isolated ostium secundum ASD repair in which bleeding risk is very low, or if they required emergency cardiac surgery. Parental consent was obtained for children younger than 16 years. Direct consent was obtained for children aged 16 years. A detailed study protocol is reported elsewhere.²⁴

Surgical and blood management procedures

All the children were managed according to a standard institutional anaesthetic protocol described previously²⁵. A bolus dose of heparin 300-400 units/Kg was administered before

aortic cannulation with additional doses of 100 units/kg to maintain an activated clotting time (ACT) >400 s. Protamine (10 mg/1000 units of heparin administered) was given at the end of CPB with additional boluses of 2-4 mg given sequentially until the ACT was <150s. Protamine was also administered after return of pump blood (5mg/100ml) which was also ultra-filtrated for all neonates and children <10Kg. Tranexamic acid (30-80 mg/kg total dose) and cell-savers for redo procedures and for complex aortic valve procedures were used according to the discretion of the anaesthesiologist. The administration of tranexamic acid and protamine as part of this standard protocol was planned before surgery and not given in response to abnormal bleeding. These interventions were classified as *pre-planned preventative treatments*.

Anesthesiologists also administered pro-haemostatic treatments hereafter termed *treatments in response to bleeding* in two circumstances: i.) during surgery if there was excessive chest cavity bleeding unattributable to a surgical bleeding point, or ii.) after surgery if there was concern about the rate of blood loss from chest drains or if there was indirect evidence of bleeding such as unexplained hypotension or anaemia. These treatments were usually selected using thromboelastography or ACT tests performed in the operating theatre of intensive care unit but in some emergency circumstances, treatments were selected empirically based on clinical circumstances. The results of the coagulation tests performed in the study were unavailable to clinicians and did not influence the choice of whether or not to administer pro-haemostatic treatments.

The clinical teams recorded administration and the indication for any pro-haemostatic treatment (fresh frozen plasma, cryoprecipitate, platelet concentrates, or additional protamine given after initial correction of the ACT at the end of CPB) that was administered between

anaesthetic induction and the first 12 hours after insertion of chest drains. Case report forms and where necessary the primary anaesthetic records were subsequently inspected by senior clinical members of the research team for all interventions recorded as *treatments in response to bleeding* to confirm correct classification.

Outcomes

The primary outcome was clinical concern about bleeding (CCB) defined as either of the following events in the interval between the start of surgery and 12 hours after insertion of chest drains: i.) administration of any pro-haemostatic treatment in response to bleeding, or, ii.) a chest drain volume of either >5ml/Kg /hr in any 1 hour interval or >3ml/kg/hr for 3 consecutive hours²⁶ (relevant for the post-operative interval only).

Pro-haemostatic treatments in response to bleeding were included in the primary outcome since it was not otherwise possible to capture excessive bleeding that occurred before the insertion of chest drains or when excessive bleeding was detected and treated after chest drain insertion before reaching the pre-designated volume threshold. Pre-planned preventative pro-haemostatic treatments were not included in the primary outcome because they were administered to children before any excessive bleeding occurred and were planned before surgery according to the blood management protocol.

The secondary outcomes were administration of any blood transfusion given within 12 hours of surgery or post-operative complications (Supplementary table S1). Post-operative complications were classified as serious if they were judged by the treating clinicians as likely to have increased the length of hospital stay, to have been life threatening or if the complication caused persistent or significant disability or resulted in death.

169

170 **Blood samples and laboratory testing**

171 A pre-operative blood sample was taken after anaesthetic induction but before
172 anticoagulation with heparin. A post-CPB blood sample was taken after completion of
173 protamine reversal of heparin anticoagulation at the end of CPB, but before the return of
174 pump blood, insertion of chest drains and chest closure. Both blood samples were analysed
175 using Sysmex XN and CS-2100 series blood count and coagulation analysers (Sysmex Corp.
176 Kobe, Japan), a Multiplate platelet function analyser (Roche Diagnostics, Switzerland) and a
177 ROTEM delta thromboelastometer (TEM International GmbH, Germany). A total of 17 test
178 results or derived parameters were pre-specified as potential predictors of the primary
179 outcome. The blood test results were unavailable to the clinicians responsible for the care of
180 the patients.

181

182 **Selection of clinical predictors**

183 The *baseline characteristics* of the children that were pre-specified as potential predictors of
184 CCB were those characteristics known to the surgical teams at the start of surgery. These
185 comprised patient age (0-28 days old *vs* older), sex, RACHS-1 category of the planned
186 procedure²⁷ weight-for-age z-score using the British 1990 Growth Reference data, pre-
187 operative anti-thrombotic medication (aspirin, warfarin or other anticoagulants at admission
188 for surgery), pre-operative prostin, and pre-operative haemoglobin level. The *surgical*
189 *characteristics* were potential predictors only known to the surgical teams at the end of
190 cardiac surgery and comprised total CPB time, aortic cross-clamp time, minimum
191 temperature during CPB, use of cell saver, return of pump blood, blood transfusion during
192 surgery and the presence of CCB during surgery.

193

Statistical analysis

In order to evaluate how well coagulation test results predicted CCB during surgery and after surgery, three sets of predictive models were generated: i.) pre-operative test results versus CCB during surgery; ii.) post-CPB test results versus CCB after surgery, and, iii.) pre-operative test results versus CCB after surgery. For each set of models, the association between the coagulation test results and CCB was assessed alongside the association between the clinical characteristics and CCB. Finally, both the clinical characteristics and coagulation test results were assessed in the same model, to test whether there was improvement in model fit.

The analysis population for the models of CCB during surgery was all children who had collection of the pre-operative blood sample and for the models of CCB after surgery was all children who had collection of the post-CPB blood sample. Multiple imputation methods using predictive mean matching and ten imputations was used for children with missing clinical characteristics or coagulation test results. Multivariable fractional polynomial models were used to allow for non-linearity of terms²⁸ using the *mfpmi* command in Stata, which builds multivariable fractional polynomial models in multiply imputed data. In addition to adjustment for the pre-specified predictors of CCB, the models were additionally adjusted for whether the patient was in the intervention arm of either of two concurrent trials (Thermic-2 ISRCTN81773762: (22 children) and OXIC-2 ISRCTN13467772: 11 children). In the models that included the coagulation test results, automated backward elimination was used to identify the test results that contributed significantly to the final model using cut-off of 0.05 in most cases, but this was increased to 0.10 if this did not result in the selection of terms. The overall effectiveness of the models in predicting CCB was reported using the *c-statistic* with 95% confidence intervals (95% CI) with differences between these tested using

the DeLong method.²⁹ The percentage of children correctly classified in each model has having CCB or no CCB was calculated using the non-imputed data. These analyses were repeated for assessing the associations with the secondary outcomes.

RESULTS

Study population

Of the 441 children who were assessed for eligibility, 75 were ineligible and 58 were eligible but were not approached for other reasons (Figure 1). Of the 308 children who were approached, consent to participate was obtained for 242 (79%). The overall analysis population for which data were collected was 225 children. Coagulation test results from all 225 children were included in the CCB during surgery models. For the CCB after surgery models, results from three children were excluded because the post-CPB blood samples could not be collected at the correct time. Imputation of at least one missing test result or clinical characteristic was required for seven of 225 (3%) children for the CCB during surgery models and for 20 of 222 (9%) children for the CCB after surgery models.

Baseline and surgical clinical characteristics

The clinical characteristics of the overall study group are shown in Table 1 and in Supplementary tables S2 and S3. The median age of the children was 1.3 years (range 2 days to 16.9 years). A total of 119 the children (53% of the overall analysis population) were male. The most common surgical procedures were bidirectional Glenn shunts or the Fontan procedure (14%) and repair of tetralogy of Fallot (13%). Most procedures had RACHS-1 category of two or three (88%). For 33% of procedures, the children had had at least one previous cardiac surgery procedure.

Of the 225 children in the overall analysis population, 26 (12%) had CCB during surgery, because they received a pro-haemostatic treatment in response to bleeding. A total of 68 (30%) had CCB after surgery of which 53 had a pro-haemostatic treatment in response to bleeding without having high chest-drain loss (Table 2). Sixty children (27%) had the secondary outcome of any blood transfusion after surgery, 99 (44%) any post-CPB complication and 62 (28%) any serious post-CPB complication (Table 2).

Coagulation test results

The prospective coagulation test results from the overall analysis population are shown in Table 3, in Supplementary Tables S2 and S4 and Figures S1 and S2. The main differences in the post-CPB results compared to the pre-operative results were reduced platelet count and platelet function (reduced PLT and reduced AUCs for the Multiplate tests), dysfunctional coagulation pathway (prolonged PT or APTT and reduced ETP), reduced fibrinogen (reduced FIB) and the persistent heparin after protamine reversal (increased anti-Xa). These changes were reflected in the ROTEM results which showed higher CT and lower MCF (EXTEM and INTEM) and lower MCF (FIBTEM) in the post-CPB samples, compared to the pre-operative samples (Table 3).

Prediction of clinical concern about bleeding during surgery

When considered individually, none of the baseline characteristics were associated with a statistically significant difference in odds ratio of CCB during surgery (Figure 2A), but when incorporated into a model they enabled prediction of CCB during surgery with a *c-statistic* of 0.64 (95% confidence interval 0.53, 0.76). The alternative model incorporating the pre-operative coagulation test results alone enabled prediction of CCB during surgery with a *c-statistic* of 0.65 (0.56, 0.76). A combined model that incorporated both the baseline

characteristics and the pre-operative coagulation test results had a *c-statistic* of 0.79 (0.70, 0.87), representing a statistically significant ($p=0.01$) improvement in model fit (Figure 2B). However, the number of children correctly predicted to have either CCB or no CCB during surgery was 198 with the baseline characteristics alone model and 200 with combined model, corresponding to an uplift in correct classification in only 0.9% of children.

Prediction of clinical concern about bleeding after surgery

The baseline characteristics female sex, higher RACHS1 category, and the surgical characteristics increased total CPB time and no use of cell saver were independent predictors of CCB after surgery (Figure 3A). The model incorporating the baseline and surgical characteristics enabled prediction of CCB after surgery with a *c-statistic* of 0.74 (0.67, 0.82). The model incorporating only the post-CPB coagulation test results enabled prediction of CCB after surgery with a *c-statistic* of 0.59 (0.51, 0.68). The combined model that incorporated the baseline and surgical characteristics and also the post-CPB coagulation test results had a *c-statistic* of 0.80 (0.74, 0.87), representing a statistically significant ($p=0.02$) improvement in model fit (Figure 3B). The number of children correctly predicted to have CCB or no CCB after surgery was 163 with the baseline and surgical characteristics alone model and 164 children with the combined model, corresponding to an uplift in correct classification in only 0.4% of children. The final fitted combined models are shown in Supplementary Table S5.

A similar analysis was performed to assess whether CCB after surgery could be predicted using only the baseline characteristics of the children and the pre-operative coagulation test results. Similar to the previous findings, CCB after surgery could be predicted using a model incorporating baseline characteristics alone (*c-statistic* 0.72 CI 0.64, 0.79), but this was not

improved by incorporating the pre-operative coagulation test results (*c-statistic* 0.74 CI 0.66, 0.81; test of equality $p=0.25$) (Supplementary Figures S3 and S4).

Prediction of the secondary outcomes

The clinical characteristics of the children and the post-CPB coagulation test results according to presence or absence of each secondary outcomes are reported in Supplementary tables S6 and S7. For all of the secondary outcomes, the predictive models incorporating the clinical characteristics alone had higher *c-statistics* than the corresponding models incorporating the post-CPB coagulation test results (Table 4). There was no further increase in *c-statistic* after combining the clinical and test result models.

DISCUSSION

In this prospective study of 225 children having a wide range of cardiac surgery procedures, we evaluated how well prospective coagulation testing at anaesthetic induction or just after CPB improved the prediction of CCB, when compared to prediction using clinical characteristics alone. The main finding was that the predictive models that incorporated clinical characteristics were improved after coagulation test results were included in the models. However, this resulted in an increase in correct prediction in only 0.9% of children for CCB during surgery and 0.4% of children for CCB after surgery. Incorporation of prospective coagulation test results did not improve prediction of blood transfusion or post-CPB complications (Figure 4).

Predictive models using clinical characteristics

We found a trend towards more frequent CCB in younger children and those receiving anti-thrombotic drugs at the point of admission for surgery, similar to previously reports.^{1, 22} CCB after surgery was associated with more complex planned surgery (high RACHS-1 score),

increased total CPB time and no use of cell saver, which also reproduces previous findings.^{1, 15, 22, 23} The association between CCB after surgery and increased duration of CPB supports previous observations that activation and consumption of platelets, clotting factors and fibrinogen by the extracorporeal CPB circuit results in significant coagulopathy.⁵ The association between CCB after surgery and no use of cell saver likely reflects that without a cell saver, blood volume is typically restored using crystalloid or red cell blood transfusion which have no haemostatic activity and have previously been shown to increase pro-haemostatic treatments when compared to cell saver blood.³⁰

Contribution of prospective coagulation test results

The coagulation test results showed complex abnormalities in platelet number and function, coagulation pathway function and in fibrinogen activity that frequently co-existed in the same blood sample, similar to previous studies.⁸⁻¹⁰ Although there were abnormalities in some pre-operative blood test results, abnormal results were more frequent in the post-CPB blood samples, indicating development of coagulopathy during surgery and consistent with the known effects of CPB and interventions such as heparin anticoagulation.⁵

Coagulation test results consistently associated with bleeding in previous studies including low platelet count²², viscoelastometric clot strength reflecting the contribution of both platelet and fibrinogen to haemostasis (ROTEM MCF or TEG MA tests)^{15, 19, 22} or low fibrinogen (ROTEM FIBTEM MCF or FIB).^{15, 23} were included in the test panel evaluated in our study. However, uniquely in our study we revealed that the additional value of using these and other test results for prediction of CCB is very low if prediction is already performed using clinical characteristics alone. This conclusion was the same for the secondary outcomes of blood transfusion or post-operative complications which are potential

consequences of bleeding.^{3, 4, 31, 32} This suggests that the main underlying causes of coagulopathy were reflected in the clinical characteristics of the cases which were thereby sufficient to drive the predictive models and that demonstration of an abnormal results in prospective coagulation tests provided little clinically useful information.

Strengths and weaknesses

The main strength of the DECISION study was the features of the study design that minimised the risk of bias: (i) the study enrolled unselected children having a wide range of procedures, (ii) 79% of the eligible children who were approached were enrolled into the study and had data collected, and (iii) the coagulation tests were performed using standardised methodology in a remote laboratory so that the results could not influence the study outcomes.

It is also a strength that the primary outcome was a composite of high blood loss observed from chest drains in the post-operative period but also the administration of any pro-haemostatic product for the treatment of bleeding. This pragmatic definition enabled identification of children with excessive bleeding during surgery before chest drain insertion, but also after surgery when pro-haemostatic treatments early in the course of bleeding frequently arrest bleeding before the threshold values for chest drain blood loss are reached. Although this approach is likely to have captured all episodes of excessive bleeding, it is possible that some pro-haemostatic treatments may have been given without evidence of excessive bleeding resulting in incorrect classification of children as having reached the primary outcome. Conversely a very small number of children may have received treatments in response to bleeding that were not documented as such. We minimised the impact of these potential errors by ensuring that a contemporaneous record was made of the indication for

each pro-haemostatic treatment and by reviewing the clinical record to ensure that these were correctly classified.

It is a potential weakness of the study that since it was conducted in a single centre the findings may not be generalizable to other centres. However, the characteristics of the children were similar to those in other predictive modelling studies^{22, 23} and to children at other Paediatric cardiac surgery centres³³, with the exception that the number of neonates enrolled to our study was lower. This is a likely consequence of exclusion of patients with body weight <2.5 Kg, which was an ethical constraint to minimise the impact of large blood samples needed for comprehensive coagulation testing. This precluded inclusion of neonates in which bleeding is prevalent and prevents generalisation of our findings to this age group. Incorporation of more recently validated procedural complexity scores such as EACTS STAT instead of RACHS-1 and including repeat sternotomy and more detailed age classifications as terms may potentially have improved performance of the clinical characteristics models. However, these measures would have been unlikely to influence the impact of including coagulation test results to these models, which was the main subject of study.

Clinical impact of the study findings

There is now abundant evidence that incorporation of coagulation test results into blood management algorithms assists selection of targeted pro-haemostatic treatments and reduces blood component use.³⁴ In this study, we evaluated the utility of prospective coagulation testing to predict excessive bleeding. Our findings support the use of clinical characteristics that are readily available either before surgery or during the course of surgery to assist prediction of bleeding. However, our findings do not currently support prospective coagulation testing to improve prediction if clinical characteristics are already considered.

REFERENCES

- [1] Williams GD, Bratton SL, Ramamoorthy C: Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. *Anesth Analg* 1999, 89:57-64.
- [2] Keung CY, Smith KR, Savoia HF, Davidson AJ: An audit of transfusion of red blood cell units in pediatric anesthesia. *Paediatr Anaesth* 2009, 19:320-8.
- [3] Wolf MJ, Maher KO, Kanter KR, Kogon BE, Guzzetta NA, Mahle WT: Early postoperative bleeding is independently associated with increased surgical mortality in infants after cardiopulmonary bypass. *J Thorac Cardiovasc Surg* 2014, 148:631-6 e1.
- [4] Guzzetta NA, Allen NN, Wilson EC, Foster GS, Ehrlich AC, Miller BE: Excessive postoperative bleeding and outcomes in neonates undergoing cardiopulmonary bypass. *Anesth Analg* 2015, 120:405-10.
- [5] Paparella D, Brister SJ, Buchanan MR: Coagulation disorders of cardiopulmonary bypass: a review. *Intensive Care Med* 2004, 30:1873-81.
- [6] Toulon P, Berruyer M, Brionne-Francois M, Grand F, Lasne D, Telion C, Arcizet J, Giacomello R, De Pooter N: Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges. *Thromb Haemost* 2016, 116:9-16.
- [7] Miller BE, Guzzetta NA, Tosone SR, Miller JL, Flunker AR, Silvey EM, Levy JH: Tissue factor-activated thromboelastograms in children undergoing cardiac surgery: baseline values and comparisons. *Anesth Analg* 2003, 97:1289-93.
- [8] Romlin BS, Soderlund F, Wahlander H, Nilsson B, Baghaei F, Jeppsson A: Platelet count and function in paediatric cardiac surgery: a prospective observational study. *Br J Anaesth* 2014, 113:847-54.

418 [9] Faraoni D, Willems A, Savan V, Demanet H, De Ville A, Van der Linden P: Plasma
 419 fibrinogen concentration is correlated with postoperative blood loss in children undergoing
 420 cardiac surgery. A retrospective review. *Eur J Anaesthesiol* 2014, 31:317-26.

421 [10] Mossad EB, Machado S, Apostolakis J: Bleeding following deep hypothermia and
 422 circulatory arrest in children. *Semin Cardiothorac Vasc Anesth* 2007, 11:34-46.

423 [11] Romlin BS, Soderlund F, Wahlander H, Hallhagen S, Wessman C, Baghaei F, Jeppsson
 424 A: Perioperative monitoring of platelet function in paediatric cardiac surgery by
 425 thromboelastometry, or platelet aggregometry? *Br J Anaesth* 2016, 116:822-8.

426 [12] Rizza A, Ricci Z, Pezzella C, Favia I, Di Felice G, Ranucci M, Cogo P: Kaolin-activated
 427 thromboelastography and standard coagulation assays in cyanotic and acyanotic infants
 428 undergoing complex cardiac surgery: a prospective cohort study. *Paediatr Anaesth* 2017,
 429 27:170-80.

430 [13] Romlin BS, Wahlander H, Berggren H, Synnergren M, Baghaei F, Nilsson K, Jeppsson
 431 A: Intraoperative thromboelastometry is associated with reduced transfusion prevalence in
 432 pediatric cardiac surgery. *Anesth Analg* 2011, 112:30-6.

433 [14] Kane LC, Woodward CS, Husain SA, Frei-Jones MJ: Thromboelastography--does it
 434 impact blood component transfusion in pediatric heart surgery? *J Surg Res* 2016, 200:21-7.

435 [15] Nakayama Y, Nakajima Y, Tanaka KA, Sessler DI, Maeda S, Iida J, Ogawa S, Mizobe
 436 T: Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and
 437 red cell transfusion after paediatric cardiac surgery. *Br J Anaesth* 2015, 114:91-102.

438 [16] Faraoni D, Willems A, Romlin BS, Belisle S, Van der Linden P: Development of a
 439 specific algorithm to guide haemostatic therapy in children undergoing cardiac surgery: a
 440 single-centre retrospective study. *Eur J Anaesthesiol* 2015, 32:320-9.

441 [17] Timpa JG, O'Meara LC, Goldberg KG, Phillips JP, Crawford JH, Jackson KW, Alten
 442 JA: Implementation of a Multidisciplinary Bleeding and Transfusion Protocol Significantly

443 Decreases Perioperative Blood Product Utilization and Improves Some Bleeding Outcomes. J
 444 Extra Corpor Technol 2016, 48:11-8.

445 [18] Whitney G, Daves S, Hughes A, Watkins S, Woods M, Kreger M, Marincola P, Chocron
 446 I, Donahue B: Implementation of a transfusion algorithm to reduce blood product utilization
 447 in pediatric cardiac surgery. Paediatr Anaesth 2013, 23:639-46.

448 [19] Moganasundram S, Hunt BJ, Sykes K, Holton F, Parmar K, Durward A, Murdoch IA,
 449 Austin C, Anderson D, Tibby SM: The relationship among thromboelastography, hemostatic
 450 variables, and bleeding after cardiopulmonary bypass surgery in children. Anesth Analg
 451 2010, 110:995-1002.

452 [20] Hayashi T, Sakurai Y, Fukuda K, Yada K, Ogiwara K, Matsumoto T, Yoshizawa H,
 453 Takahashi Y, Yoshikawa Y, Hayata Y, Taniguchi S, Shima M: Correlations between global
 454 clotting function tests, duration of operation, and postoperative chest tube drainage in
 455 pediatric cardiac surgery. Paediatr Anaesth 2011, 21:865-71.

456 [21] Andreasen JB, Hvas AM, Christiansen K, Ravn HB: Can RoTEM(R) analysis be applied
 457 for haemostatic monitoring in paediatric congenital heart surgery? Cardiol Young 2011,
 458 21:684-91.

459 [22] Williams GD, Bratton SL, Riley EC, Ramamoorthy C: Coagulation tests during
 460 cardiopulmonary bypass correlate with blood loss in children undergoing cardiac surgery. J
 461 Cardiothorac Vasc Anesth 1999, 13:398-404.

462 [23] Miller BE, Mochizuki T, Levy JH, Bailey JM, Tosone SR, Tam VK, Kanter KR:
 463 Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth
 464 Analg 1997, 85:1196-202.

465 [24] Underwood W, Rogers CA, Plummer Z, B CR, Caputo M, Murphy P, Sheehan K, Harris
 466 J, Culliford L, Mumford A: Detection of coagulopathy in paediatric heart surgery
 467 [DECISION study]: study protocol. BMC Hematol 2015, 15:11.

468 [25] Caputo M, Patel N, Angelini GD, de Siena P, Stoica S, Parry AJ, Rogers CA: Effect of
469 normothermic cardiopulmonary bypass on renal injury in pediatric cardiac surgery: a
470 randomized controlled trial. *J Thorac Cardiovasc Surg* 2011, 142:1114-21, 21 e1-2.

471 [26] Pekelharing J, Furck A, Banya W, Macrae D, Davidson SJ: Comparison between
472 thromboelastography and conventional coagulation tests after cardiopulmonary bypass
473 surgery in the paediatric intensive care unit. *Int J Lab Hematol* 2014, 36:465-71.

474 [27] Jenkins KJ, Gauvreau K: Center-specific differences in mortality: preliminary analyses
475 using the Risk Adjustment in Congenital Heart Surgery (RACHS-1) method. *J Thorac*
476 *Cardiovasc Surg* 2002, 124:97-104.

477 [28] Zhang Z: Multivariable fractional polynomial method for regression model. *Ann Transl*
478 *Med* 2016, 4:174.

479 [29] DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more
480 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*
481 1988, 44:837-45.

482 [30] Cholette JM, Powers KS, Alfieri GM, Angona R, Henrichs KF, Masel D, Swartz MF,
483 Daugherty LE, Belmont K, Blumberg N: Transfusion of cell saver salvaged blood in neonates
484 and infants undergoing open heart surgery significantly reduces RBC and coagulant product
485 transfusions and donor exposures: results of a prospective, randomized, clinical trial. *Pediatr*
486 *Crit Care Med* 2013, 14:137-47.

487 [31] Salvin JW, Scheurer MA, Laussen PC, Wypij D, Polito A, Bacha EA, Pigula FA,
488 McGowan FX, Costello JM, Thiagarajan RR: Blood transfusion after pediatric cardiac
489 surgery is associated with prolonged hospital stay. *Ann Thorac Surg* 2011, 91:204-10.

490 [32] Iyengar A, Scipione CN, Sheth P, Ohye RG, Riegger L, Bove EL, Devaney EJ, Hirsch-
491 Romano JC: Association of complications with blood transfusions in pediatric cardiac
492 surgery patients. *Ann Thorac Surg* 2013, 96:910-6.

[33] https://web.nicor.org.uk/_80257061003D4478.nsf/vwContent/home?OpenDocument.

[34] Machovec KA, Jooste EH: Pediatric Transfusion Algorithms: Coming to a Cardiac Operating Room Near You. J Cardiothorac Vasc Anesth 2019, 33:2017-29.

ACKNOWLEDGEMENTS: This study was funded by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. This study was designed and delivered in collaboration with the Clinical Trials and Evaluation Unit, Bristol Trials Centre, a UKCRC registered clinical trials unit, which is in receipt of NIHR CTU support funding. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The British Heart Foundation provided additional support. We acknowledge the contribution of Dr Zoe Plummer and Wendy Underwood (Clinical Trials Coordinators), Kathy Selway (Paediatric Cardiac Nurse Specialist) and Mary Walker (research assistant) to the delivery of this study.

Figure 1: Flow of study participants. The flow chart indicates the number of children who were assessed for eligibility, approached to participate, consented to join the study and the number for which complete study datasets were collected (white boxes). The gray boxes indicate the reasons why some children who were assessed for eligibility were not part of the analysis population.

Figure 2: Prediction of excessive bleeding during surgery. A. Associations between the baseline clinical characteristics and clinical concern about bleeding (CCB) during surgery presented as adjusted odds ratios with 95% confidence intervals (CI). **B.** Receiver operator characteristic (RoC) curves of the predictive models for CCB during surgery incorporating the baseline clinical characteristics alone and for a combined model that also incorporated the prospective pre-operative coagulation test results. The areas under the curves (c-statistics) indicate better prediction for the combined model. RACHS-1: Risk adjustment in Congenital Heart Surgery-1. The test of equality value indicates evidence of difference between the RoC curves.

Figure 3: Prediction of excessive bleeding after surgery. A. Associations between the baseline and surgical clinical characteristics of the children and clinical concern about bleeding (CCB) after surgery presented as adjusted odds ratios with 95% confidence intervals (CI). **B.** Receiver operator characteristic (RoC) curves of the predictive models for CCB after surgery incorporating the baseline and surgical characteristics alone and for a combined model that also incorporated the prospective post-CPB coagulation test results. The areas under the curves (c-statistics) indicate better prediction for the combined model. RACHS-1: Risk adjustment in Congenital Heart Surgery-1. The test of equality value indicates evidence of difference between the RoC curves.

Prediction of bleeding using clinical characteristics improves little after including coagulation test results

Figure 4: Graphical abstract

This study overview highlights that from a study population of 225 children undergoing a wide range of cardiac surgery procedures, candidate predictors of bleeding were pre-selected from either the clinical characteristics of the children and from the results of a panel of prospective coagulation tests performed at anaesthetic induction and just after the end of cardiopulmonary bypass. The primary outcome was clinical concern about bleeding, a composite endpoint to reflect excessive bleeding. Predictive models were generated using clinical characteristics alone or in combination with prospective coagulation test results. Although including coagulation test results to the models that already included clinical characteristics improved prediction of CCB, the clinical impact expressed as the improvement in the number of children with correct classification was very small.

— Clinical characteristics model; c-statistic=0.74

— Best Clinical characteristics plus test results model; c-statistic=0.80

CENTRAL PICTURE LEGEND: Bleeding prediction models

improves little after including coagulation test results.

FIGURE 1

FIGURE 2**A** **B**

— Clinical characteristics model; c-statistic=0.64
— Best Clinical characteristics plus test results model; c-statistic=0.79
Test of equality: $p=0.01$

FIGURE 3**A** **B**

— Clinical characteristics model; c-statistic=0.74
 — Best Clinical characteristics plus test results model; c-statistic=0.80
 Test of equality: $p=0.02$

Prediction of bleeding using clinical characteristics improves little after including coagulation test results

Table 1: Description of the study cohort

		All patients (n=225)
Sex; n (%) males		119 (53%)
Age categories	Neonate (0-28 days)	12 (5%)
	Older child (>28 days)	213 (95%)
Weight-for-age z-scores		-1.3 (-2.5, -0.3)
Surgical procedure	Bidirectional Glenn shunts or Fontan	31 (14%)
	Tetralogy of Fallot repair	30 (13%)
	VSD repair	23 (10%)
	Atrioventricular septal defect repair	22 (10%)
	Complex or multiple procedures	16 (7%)
	Sub- or supra- aortic stenosis repair	14 (6%)
	VSD + minor defect repair	12 (5%)
	Conduit replacements	12 (5%)
	Pulmonary valve replacement	10 (4%)
	VSD + major defect repair	10 (4%)
	Transposition of great arteries repair	9 (4%)
	Ross-Konno procedure	7 (3%)
	RVOT repair	7 (3%)
	AV valve repair/replacement	7 (3%)
	Aortic valve repair	5 (2)
	Atrial septal defect repair all	3 (1%)
	Interrupted arch repair	3 (1%)
	PAPVD or TAPVD repair	2 (1%)
	Norwood procedure	1 (0%)
	Truncus repair	1 (0%)
RACHS-1 complexity	1	4 (2%)
	2	115 (51%)
	3	83 (37%)
	4	20 (9%)
	6	3 (1%)
Repeat sternotomy		75 (33%)
Pre-operative antithrombotic medication		44 (20%)
Pre-operative haemoglobin (g/dL)		122 (108, 137)
Cardiopulmonary bypass time (min)		92 (71, 130)
Cross clamp time (if used) (min)		60 (36, 88)
Minimum temperature during CPB (°C)		32 (31, 34)
Cell saver used (yes)		33 (15%)
If yes, volume returned (mL)/weight (kg)		8.3 (5.5, 11.8)
Pump blood returned (yes)		140 (63%)
If yes, volume (mL)/weight (kg)		8.9 (5.9, 12.1)
Red cell transfusion during surgery (units*)	0	168 (75%)
	1	55 (24%)
	2	2 (1%)

AVSD, Atrioventricular Septal Defect; VSD, Ventricular Septal Defect; AV, atrioventricular; PAPVD, Partial Anomalous Pulmonary Venous drainage; TAPVD, Total Anomalous Pulmonary Venous Drainage; RACHS, Risk adjustment for congenital heart surgery. The continuous variables are described as median and interquartile ranges. * data refer to the number of allogenic red cell units administered

Table 2: The frequencies of the primary and secondary outcomes

Primary outcome	
Clinical concern about bleeding during surgery	26 (12%)
Pro-haemostatic treatment in response to bleeding during surgery	26 (12%)
Fresh frozen plasma	1
Cryoprecipitate	16
Platelet transfusion	15
Additional protamine	3
Clinical concern about bleeding after surgery	68 (30%)
Pro-haemostatic treatment in response to bleeding after surgery	53 (24%)
Fresh frozen plasma	9
Cryoprecipitate	33
Platelet transfusion	41
Additional protamine	7
High chest-drain volume ¹	15 (7%)
High chest-drain volume ¹ and non-routine pro-haemostatic treatment after surgery	9 (4%)
Secondary outcomes	
i. Any blood transfusion after surgery	60 (27%)
ii. Any post-operative complications	99 (44%)
Arrhythmias	58 (26%)
Pulmonary complication	27 (12%)
Haemodynamic support required	23 (10%)
Renal complication	11 (5%)
Neurological complication	11 (5%)
Infective complication	10 (4%)
Pericardial effusion	7 (3%)
Death during hospital admission	4 (2%)
Cardiac arrest	4 (2%)
Gastrointestinal tract complication	4 (2%)
iii. Any serious post-operative complications	62 (28%)

Frequencies are expressed relative to the overall analysis population of 225 children. 1
Defined as chest drain volume >5mL/Kg/hr in any one hour interval after surgery or chest
drain volume >3mL/Kg/hr for 3 consecutive hours after surgery

Table 3: Coagulation test results

	Pre-operative blood sample (n=225)	Post-CPB blood sample (n=222)
PLT (x10 ⁹ /L) ¹	269.5 (220.5, 348.5)	152.0 (114.0, 198.0)
PT (s) ²	11.5 (11.1, 12.2)	14.3 (13.4, 15.4)
APTT (s) ²	30.5 (28.7, 32.8)	40.3 (34.7, 51.2)
FIB (g/L) ¹	1.9 (1.6, 2.3)	1.1 (0.9, 1.4)
anti-Xa (u/mL) ³	0.1 (0.0, 0.1)	0.3 (0.2, 0.5)
ADP-test AUC (U) ⁴	724.0 (571.0, 889.0)	362.5 (242.0, 526.0)
TRAP-test AUC (U) ⁴	1047.0 (905.0, 1238.0)	888.5 (599.0, 1169.0)
COLL-test AUC (U) ⁵	631.0 (502.0, 747.0)	478.5 (321.5, 676.0)
ETP (nM/min)	823.1 (643.9, 980.4)	193.4 (47.4, 383.1)
INTEM CT (s) ⁶	198.0 (176.0, 223.0)	241.0 (204.0, 286.0)
INTEM MCF (mm) ⁶	66.0 (62.0, 69.0)	56.0 (51.0, 62.0)
INTEM ML (%) ⁶	7.0 (4.0, 10.0)	2.0 (0.0, 5.0)
EXTEM CT (s) ⁷	58.0 (50.0, 67.0)	80.0 (67.0, 99.0)
EXTEM MCF (mm) ⁷	66.0 (62.0, 69.0)	57.0 (52.0, 63.0)
EXTEM ML (%) ⁶	9.0 (6.0, 13.0)	3.0 (1.0, 7.0)
FIBTEM MCF (mm) ⁷	13.0 (11.0, 16.0)	8.0 (6.0, 10.0)
INTEM CT-HEPTEM CT (s) ⁸	-2.0 (-18.0, 17.0)	2.0 (-18.0, 24.0)

PLT, platelet count; PT, prothrombin time; APTT, activated partial thromboplastin time; FIB, fibrinogen level, anti-Xa, anti-Xa heparin level; AUC, area under curve in Multiplate platelet function test; ETP, endogenous thrombin potential; CT, ROTEM thromboelastometry INTEM/EXTEM reagent clot time; MCF, ROTEM INTEM/EXTEM/FIBTEM maximum clot firmness, ML, ROTEM INTEM/EXTEM maximum lysis. Data are expressed as median and interquartile range. Missing data: ¹ 4 children; ² 5 children; ³ 34 children; ⁴ 6 children; ⁵ 8 children; ⁶ 6 children; ⁷ 5 children; ⁸ 7 children; ⁹ 2 children.

Table 4: The *c-statistics* from the predictive models for the secondary outcomes.

Model components	Red cell transfusion after surgery	Post-operative complication	Serious post-operative complication
Pre-operative and surgical clinical characteristics	0.67 (0.59, 0.75)	0.72 (0.66, 0.79)	0.73 (0.66, 0.80)
Post-CPB blood sample test results	0.59 (0.51, 0.69)	0.56 (0.48, 0.64)	0.52 (0.43, 0.62)
Combined clinical characteristics and blood test results	0.71 (0.63, 0.79)	0.75 (0.69, 0.82)	0.73 (0.66, 0.80)
<i>P</i> value for combined model vs clinical characteristics only model	0.15	0.09	0.75

[Click here to access/download](#)

Supplementary Data

R1clean_DECISION_SUPPLEMENTARY.docx

THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Required Information

Prediction of bleeding in paediatric cardiac surgery using clinical characteristics and coagulation test results

Manuscript Title: _____

Professor Andrew MumfordHarris

Corresponding Author: _____

Authorship Responsibility and Contribution

Based on "A new standard for authorship" from The Council of Science Editors (<http://tinyurl.com/lkab4jp>).

By submitting this manuscript, each author certifies that:

They made a direct and substantial contribution to the work reported in the manuscript by participating in at least the following three areas:

- made substantial contributions to conception and design and/or acquisition of data and/or analysis and interpretation of data;
- participated in drafting and/or revising the paper and provided important intellectual contributions; and
- gave final approval of the submitted version and any revised versions submitted prior to acceptance.

They participated to a sufficient degree to take public responsibility for the work and believe that the manuscript describes truthful facts. They declare that they shall produce the data on which the manuscript is based for examination by the editors or their assignees, should it be requested. Each author also agrees to allow the corresponding author to make decisions regarding submission of the manuscript to the Journal, changes to galley proofs, and prepublication release of information in the manuscript to the media, federal agencies, or both.

In the table below, please designate the substantive contribution(s) of each author.

Author Name		Conception and design	Analysis and interpretation	Writing the article	Critical revision of the article	Final approval of the article	Data Collection	Provision of materials, patients, or resources	Statistical expertise	Obtaining funding	Literature search	Administrative, technical, or logistic support
1.	Harris	✓	✓	✓	✓	✓	✓		✓			
2.	Sheehan					✓	✓	✓				✓
3.	Rogers	✓				✓			✓			
4.	Murphy		✓		✓	✓		✓				
5.	Caputo	✓			✓	✓		✓		✓		
6.	Mumford	✓	✓	✓	✓	✓				✓	✓	
7.												
*8.												
*9.												
*10.												

**If more than 7 authors are included in the manuscript, authors MUST provide an explanation in the next section for the Editor's review.*

Additional Author Explanation

The number of authors should be limited to those individuals who made direct contributions to the intellectual content of the paper. For most papers, 7 authors should be sufficient. Additional authors may be added if their inclusion can be justified and if each author is able to assume responsibility for the validity of the results and conclusions in the manuscript. **If more than 7 authors are included in the manuscript, authors MUST provide an explanation below for the Editor's review.**

not applicable

Statistical Collaboration Statement

Because data and their analyses often constitute the supporting evidence for inferences drawn from studies submitted to the Journal, the Editors remind authors that all manuscripts with statistical analyses undergo statistical review by the Journal. The review includes study design, analysis, interpretation, and reporting. The manuscripts are not published without an acceptable rating by the statistical editorial staff. Therefore, to minimize revision and delays, authors should request review of such manuscripts by a statistician prior to submission. This is best done by involving a statistician as a collaborator from the inception to completion of the study. Statisticians should have a master's or doctoral degree (or equivalent) in biostatistics or related field, and experience in the design, analysis and interpretation of biomedical data of the type used in this paper. The statistician, along with the authors, possess scientific responsibility for the analysis and interpretation of the data presented in the final version of this manuscript.

Did this manuscript require the performance of complex statistical methods? ☒ Yes ☐ No

If yes, please complete the information below regarding the statistical expert for this manuscript. **Be sure to include a short description of their area(s) of statistical expertise.**

Dr Jessica Harris and Professor Chris Rogers

Name: _____

University of Bristol, Bristol, UK

Institution: _____

Bristol Trials Centre

Department: _____

Jessica.harris@bristol.ac.uk

Email: _____

Area(s) of Statistical Expertise:

Dr Harris and Professor Rogers are the Senior statistician and Director of the Bristol Trials Centre (<https://bristoltrialscentre.blogs.bristol.ac.uk/>) which is a UKCRC-registered clinical trial unit with extensive expertise of design delivery and statistical analysis of observational and clinical trials.

Once the form has been completed, in its entirety, select "File" and "Print". Print the form to an Adobe PDF. Then upload the form to Editorial Manager.